Schizophrenia/Psychosis

Check out the latest results from the phase 3 CONNEX-X study.

Review the multiple uses of metformin.

Investigational agent KarXT is a first-in-class muscarinic receptor agonist demonstrating antipsychotic efficacy and safety in short- and long-term clinical trials.

What is new in research on schizophrenia?

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

A poster presented at the 2024 ASCP Annual Meeting discussed the results of a study on the efficacy and tolerability of the investigational schizophrenia treatment.

What are the risks and benefits of antipsychotic polypharmacy for the treatment of schizophrenia?

Sam Clark, MD, PhD, the founder and CEO of Terran Biosciences shared all you need to know about the development of their schizophrenia treatment, TerXT.

In honor of Asian American/Pacific Islander Heritage Month, we had a discussion on how best to support AAPI youth and their families.

A recent study analyzed longitudinal data of patients with schizophrenia or major depressive disorder to rank treatment regimens in terms of weight gain, adverse effects, and response to treatment.

An expert shares some clinical pearls from his lecture at the recent American Psychiatric Association Annual Meeting.

Here are highlights from the week in Psychiatric Times.

Here’s a look at our recent coverage of these disorders in honor of Mother’s Day 2024.

Gone in a puff of smoke? Researchers investigated the effectiveness of antipsychotics in reducing the risk of hospitalization in patients with first-episode psychosis and co-occurring CUD.

TEV-‘749, an investigational once-monthly subcutaneous long-acting injection of the 2nd generation antipsychotic olanzapine, sees positive phase 3 results.

A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.

Here are highlights from the fourth day of this year’s APA Annual Meeting.

The extension trial aims to address the cognitive impairment often observed in schizophrenia.

Jonathan M. Meyer, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

For the past 7 decades, there has only been 1 mechanism of action for schizophrenia treatment. Christoph Correll, MD, talks new options and cognitive impairment at the 2024 APA Annual Meeting.

This 2024 APA Annual Meeting poster estimated the prevalence of tardive dyskinesia in antipsychotic users in the US, and found rates ranging from 94.1-127.4 per 1000 antipsychotic users.

What makes this treatment option unique?

This interactive installation begs the question, “What is the truth of life with schizophrenia?”

The chief scientific officer and medical director of Segal Trials shares more on KarXT, a first in class for muscarinic agonists, and what he's excited about at the upcoming 2024 APA Annual Meeting.